183 related articles for article (PubMed ID: 28728163)
1. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients.
Wadhwa R; Wang X; Baladandayuthapani V; Liu B; Shiozaki H; Shimodaira Y; Lin Q; Elimova E; Hofstetter WL; Swisher SG; Rice DC; Maru DM; Kalhor N; Bhutani MS; Weston B; Lee JH; Skinner HD; Scott AW; Kaya DM; Harada K; Berry D; Song S; Ajani JA
Br J Cancer; 2017 Aug; 117(5):648-655. PubMed ID: 28728163
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy.
Yoshikawa R; Nakano Y; Tao L; Koishi K; Matsumoto T; Sasako M; Tsujimura T; Hashimoto-Tamaoki T; Fujiwara Y
Br J Cancer; 2008 May; 98(10):1670-4. PubMed ID: 18475300
[TBL] [Abstract][Full Text] [Related]
3. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.
Ajani JA; Wang X; Song S; Suzuki A; Taketa T; Sudo K; Wadhwa R; Hofstetter WL; Komaki R; Maru DM; Lee JH; Bhutani MS; Weston B; Baladandayuthapani V; Yao Y; Honjo S; Scott AW; Skinner HD; Johnson RL; Berry D
Mol Oncol; 2014 Feb; 8(1):142-9. PubMed ID: 24210755
[TBL] [Abstract][Full Text] [Related]
4. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer.
Zhang JL; Wang HY; Yang Q; Lin SY; Luo GY; Zhang R; Xu GL
World J Gastroenterol; 2015 Apr; 21(14):4240-7. PubMed ID: 25892874
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.
Kordes S; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; van der Vliet HJ; Kapiteijn E; van Laarhoven HW; Richel DJ; Klinkenbijl JH; Meijer SL; Wilmink JW
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):190-6. PubMed ID: 25195993
[TBL] [Abstract][Full Text] [Related]
8. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
10. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.
Blum Murphy M; Xiao L; Patel VR; Maru DM; Correa AM; G Amlashi F; Liao Z; Komaki R; Lin SH; Skinner HD; Vaporciyan A; Walsh GL; Swisher SG; Sepesi B; Lee JH; Bhutani MS; Weston B; Hofstetter WL; Ajani JA
Cancer; 2017 Nov; 123(21):4106-4113. PubMed ID: 28885712
[TBL] [Abstract][Full Text] [Related]
11. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
12. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
13. Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer?
Imdahl A; Jenkner J; Ihling C; Rückauer K; Farthmann EH
Am J Surg; 2000 Jun; 179(6):514-20. PubMed ID: 11004343
[TBL] [Abstract][Full Text] [Related]
14. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).
Yoon HH; Ou FS; Soori GS; Shi Q; Wigle DA; Sticca RP; Miller RC; Leenstra JL; Peller PJ; Ginos B; Heying E; Wu TT; Drevyanko TF; Ko S; Mattar BI; Nikcevich DA; Behrens RJ; Khalil MF; Kim GP; Alberts SR
Eur J Cancer; 2021 Jun; 150():214-223. PubMed ID: 33934058
[TBL] [Abstract][Full Text] [Related]
15. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
[TBL] [Abstract][Full Text] [Related]
16. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
Ajani JA; Correa AM; Walsh GL; Komaki R; Lee JH; Vaporciyan AA; Rice DC; Yao JC; Maru DM; Hofstetter WL; Phan AT; Swisher SG
Cancer; 2010 Apr; 116(7):1656-63. PubMed ID: 20143431
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma.
Mallery S; DeCamp M; Bueno R; Mentzer SJ; Sugarbaker DJ; Swanson SJ; Van Dam J
Cancer; 1999 Sep; 86(5):764-9. PubMed ID: 10463973
[TBL] [Abstract][Full Text] [Related]
18. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
Ajani JA; Wang X; Izzo JG; Crane CH; Eng C; Skibber JM; Das P; Rashid A
Dig Dis Sci; 2010 Apr; 55(4):1098-105. PubMed ID: 19399614
[TBL] [Abstract][Full Text] [Related]
19. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
[TBL] [Abstract][Full Text] [Related]
20. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
